With shortages in labour and resources in the US healthcare system, medium-sized funds have a unique role to play to bridge the gaps.

Personalised treatment, combination therapies, vaccines and of course AI: pharmaceutical investors are backing a surge of new cancer technologies.

The longed-for recovery in startup exits hasn't yet arrived. But those startups that did get bought or publicly listed in September did so at higher prices.

The Canadian venture firm is opening an office in Asia as Asian corporations flock to invest in its fifth fund and largest fund.

Berger will lead the biotech investment for the Saudi city project, contributing to the Kingdom's goal of becoming a global biotech hub.

South Korean multinational Lotte Holdings has set up a CVC arm to invest in new technology in healthcare and biopharmaceuticals.

SEC filings show the CVC wants to raise its third nine-figure fund to back biotech startups.

Female-focused health startups have been receiving increased funding in 2024 and a new crop of startups is emerging to address previously underserved areas.

Maarten-Yan Wierenga is serving as interim head of NuFrontiers while Erik Tveteraas joined fungus-based protein developer NoMy as CFO.

Private equity companies have been active in buying VC-backed companies, sometimes at a significant discount. Digital and life sciences startups dominate the list of exits.